

Eradication of Polio in the World; Iran is at Risk for Reemerging of Polio: A Review of the Literature

Seyed Mansour Razavi,¹ Masoud Mardani,² and Payman Salamati^{3,*}

¹Department of Community Medicine, Tehran University of Medical Sciences, Tehran, IR Iran

²Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

³Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, IR Iran

*Corresponding author: Payman Salamati, Sina Trauma and Surgery Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, IR Iran. Tel: +98-2166757001, Fax: +98-2166757009, E-mail: salamati@tums.ac.ir

Received 2016 February 03; Accepted 2016 June 26.

Abstract

Context: The wild polio virus is disrupted in all countries in the world, except Afghanistan and Pakistan, the two neighboring countries of Iran. Because of illegal migrations and some geographical, socioeconomic and managerial problems, Iran is exposed to reemerging of the disease. The current study aimed to assess the condition of the disease in Iran and propose preventive measures.

Evidence Acquisition: Authors extracted and evaluated 33 relevant articles among 189 polio related abstracts. The key words were: polio, poliomyelitis, polio eradication, oral polio vaccine (OPV), inactivated polio vaccine (IPV), acute flaccid paralysis (AFP), vaccination derived paralysis (VDP) and Iran. PubMed was used as an international site and IranMedex as a national motor search to assess the subject.

Results: Since 2001, Iran is recognized as a polio free country by world health organization (WHO). Afghanistan and Pakistan, the two neighboring countries of Iran, are still infected with wild poliovirus. About 2.5 million Afghan refugees live in Iran and they communicate with their compatriots. Iran and its neighbors are different regarding vaccination coverage rates, rate of access to safe drinking water, political, security and cultural issues, health system and managerial indicators.

Conclusions: Health managers in Iran should continuously monitor the coverage of vaccination with at least three doses of OPV in the level of over 95%, monitor the health of the Helmand River water which comes from Afghanistan to Iran, vaccinate the immigrants and replace bivalent vaccine (bOPV) with trivalent (tOPV) vaccine.

Keywords: Poliomyelitis, Communicable Disease Control, Iran

1. Context

Poliomyelitis is a highly contagious and transmissible infectious disease which is mainly transmitted via contaminated food and drinking water by human feces (fecal-oral route) (1). The clinical spectrum outcomes are as follows:

1) Asymptomatic form (90% of cases), 2) Mild illness characterized by fever, malaise, headache, nausea, vomiting, diarrhea or constipation (9% of cases), 3) Central nervous involvement such as aseptic meningitis, 4) Paralytic form (less than 1% of cases), 5) Post-polio syndrome characterized by cold intolerance in the affected limbs, muscle pain and weakness, 30-40 years after exposure to the wild virus in childhood (2, 3).

This disease is caused by three types of polio virus (P1, P2 and P3). The most neurovirulent types are P1 and P2 known as vaccine derived poliovirus type. Immunity against one type does not protect Individuals against the other types. Several doses of oral polio vaccine (OPV) are needed to induce immunity and it provides long-term protection against poliomyelitis (4).

Humans are the main reservoir of the virus. This point provides the possibility of eradication of disease by vaccination. Thus, in 1988, the world health assembly (WHA) adopted the goal of global polio eradication by the year

2000. The objectives of this strategy were as follows: a) Immunize people with OPV, b) Achieve and maintain high coverage vaccination levels among children under five, c) Develop an appropriate epidemiologic and laboratory acute flaccid paralysis (AFP) surveillance system, d) Hold the national polio days (NPDs) (2, 5).

The current study aimed to report the status of polio eradication program in Iran and attract the attention of the authorities seriously to the possibility of emerging the disease in the country.

Glossary (2, 4, 6):

-WPV1, 2 & 3: wild poliovirus type 1, 2 & 3

-GPEI: global poliomyelitis eradication initiative

-WHA: world health assembly

-NIDs: national immunization days

-SNIDs: sub-national immunization days

-NITAG: national immunization technical advisory group

-OPV: oral polio vaccine

-IPV: inactivated (injectable) polio virus

-tOPV: trivalent oral polio virus

-bOPV: bivalent oral polio virus

-mOPV1: monovalent type-1 oral poliovirus vaccine

-VDP: vaccine derived paralysis

-VDPVs: vaccine derived polio viruses

- VAAFP: vaccine associated acute flaccid paralysis
- iVDPVs: immunodeficiency-associated vaccine derived polio viruses
- cVDPVs: circulatory-associated vaccine derived polio viruses
- aVDPVs: ambiguous vaccine derived polio viruses
- PID: primary immune deficient

2. Evidence Acquisition

PubMed was used as an international databank and IranMedex as a national motor search to assess the subject. The key words were as follows: polio, poliomyelitis and polio eradication, OPV, IPV, AFP, VDP and Iran. One hundred and eighty-nine assessed abstracts included: polio and Iran (48), poliomyelitis and Iran (34), polio eradication and Iran (7), OPV and Iran (10), oral polio vaccine and Iran (18), IPV and Iran (12), inactivated polio vaccine and Iran (3), AFP and Iran (40), acute flaccid paralysis and Iran (15), VDP and Iran (0), and vaccine derived paralysis and Iran (2). Of these abstracts, 33 articles which were entirely relevant to the study goals were evaluated. There were no deterrent ethical considerations in the study.

3. Results

3.1. Polio Vaccines

For the first time, trivalent inactivated (injectable) polio vaccine (IPV) was prepared by Jonas Edward Salk in 1952, and then live attenuated OPV was introduced by Albert Sabine in 1961 (2, 5, 7). Oral polio vaccine is formed by a combination of live and attenuated types 1, 2 and 3 of the polio viruses and is called trivalent oral polio vaccine (tOPV) (8, 9).

Since the attenuated OPV has many benefits, its consumption is accepted worldwide. Some of these advantages are as follows: ease of use, induction of efficient intestinal and durable humeral immunity and low cost. Nevertheless, the most important disadvantage of OPV is genetic instability, resulting in vaccine-associated paralytic poliomyelitis (VAPP) (10).

Mir et al. evaluated the monovalent type-1 oral poliovirus vaccine (mOPV1) immunogenicity, given with an interval of one week in Karachi, Pakistan. This study was carried out on 1009 healthy newborn babies with a birth weight of at least 2.5 kg. The authors recommended that, shortening the interval between mOPV doses to seven days could be beneficial (11).

3.2. Immunogenicity

The oral polio vaccine creates an appropriate intestinal and humeral immunity against all three biotypes of the virus. The immunity against the biotypes is not the same.

Izadi et al. in a cross-sectional study conducted on 365 children aged 20 (\pm 2) months who had received at least five doses of trivalent oral polio vaccine, evaluated serological status against three serotypes of polioviruses. In this study, seropositive children against poliovirus serotypes 1, 2 and 3 were 94.1%, 96.7% and 78.3%, respectively. They concluded that, since the immune response against polio virus type 3 (PV3) was lower than those of other serotypes, improving the population immunity against this serotype is an urgent priority (12).

In many developing countries, the immunogenicity of the three doses of OPV is lower than that of industrialized countries (13).

Habib et al. conducted a double-blind, randomized placebo-controlled trial on 404 newborns aged 0-14 days. They assessed the impact of zinc supplementation on immune response to OPV and concluded that zinc supplementation had no effect on OPV immunogenicity (14).

3.3. Vaccine-Associated Poliovirus Paralysis (VAPP)

Nowadays, the wild polio virus is eradicated in most countries, but acute flaccid paralysis (AFP) caused by the vaccine is reported in some countries. This is called vaccine derived polioviruses paralysis (VDP) (15).

Three categories of VDPVs are recognized: 1) Circulating VDPVs (cVDPVs) which occurs in the settings with low coverage of immunization by OPV, 2) Immunodeficiency-associated VDPVs (iVDPVs) which occurs in individuals with primary immunodeficiency, and 3) Ambiguous VDPVs (aVDPVs), which cannot be definitively categorized. In other words, OPV may cause paralysis in non-immune vaccine recipients. Immunodeficiency-associated vaccine derived polio viruses can replicate and be excreted for years from the body of the patients with primary immunodeficiency (4, 8, 10).

In patients with primary immune disorders (PID), especially those with B-cell system disorders, chronic excretion of polio virus rises and the risk of paralytic poliomyelitis increases (16). The first presentations of VAPP may be neurologic abnormalities in some patients with primary immunodeficiency (17).

The risk of VAPP in normal population is 1 case per 750000 and this rate in patients with immunodeficiency particularly for persons with agammaglobulinemia and hypogammaglobinemia is 1 per 7000. However, there is no appropriate estimation for patients with impaired cellular immunity (17).

Vaccine derived paralysis is caused by OPV; thus, eliminating this risk requires stopping the OPV use (8).

The majority of VDPs are associated with type 2 circulating VDPVs (cVDPV2). Therefore, it is suggested to remove type 2 virus from trivalent vaccines (tOPV) and change this vaccine to bivalent vaccines (bOPV) consisting only types 1 and 3 polioviruses.

3.4. WHA New Strategy for Polio Eradication

Since most of the vaccine induced paralytic forms are caused by polio virus type 2, according to the world health organization (WHO) suggestion, this type is removed from the oral vaccine and bOPV is used instead of tOPV in some countries since April 2016.

At least one dose of IPV is introduced prior to bOPV in routine immunization schedule (4).

Six hundred and eighty-six cases of paralytic polio were detected due to cVDPVs since 2006. More than 97% of the paralytic cases were caused by type 2 cVDPVs. Therefore, to eliminate the risk of paralytic forms by cVDPVs, OPV serotype 2 is withdrawn from all immunization programs throughout the world. Therefore, trivalent OPV (tOPV) should be replaced with bivalent OPV (bOPV) which contains only types 1 and 3 polioviruses using IPV and switching from tOPV to bOPV (8).

In 2013, the world health assembly (WHA) endorsed a plan to withdraw OPV from immunization programs in the world. This program started with the removal of type 2 component of OPV in 2016. According to this program, before the above date (by the end of 2015), at least one dose of IPV vaccine is included in routine vaccination programs of all 126 countries that use OPV (10, 18).

From June 24, 2015, among 194 WHO members, 90 countries (46%) use IPV and the others announced that they use this vaccine in 2015. Switching from tOPV to bOPV is a strategic plan from 2013 to 2018 (9-15).

3.5. Polio Eradication Status in the World

In 1988, the WHA predicted that poliomyelitis should be eradicated by the year 2000 (19). Up to 2014, the wild polio virus (WPV) transmission in all countries except Afghanistan, Pakistan and Nigeria was disrupted. (8, 9). However, reports indicate that, in 2015, Nigeria reaches one year without polio (20), promising news.

3.6. Polio Eradication Status in Iran

In 1982, an advisory committee was formed and named national immunization technical advisory group (NITAG) in Iran. It provided numerous scientific and technical recommendations to eradicate polio in the country (21). Since

1994, the Islamic Republic of Iran adopted strategies and programs to eradicate polio (19).

Mass vaccination of 10 million children under five in a national immunization day program started in 1994 and continued twice every year up to 1998. After that, the regional supplementary immunization began in the form of, sub-national immunization days (SNIDs) and still continues twice a year (19).

The last case was an imported case from Afghanistan and the circulation of wild poliovirus was stopped in December 2000 in the country and it was confirmed in 2001 by WHO and at present Iran is known as a polio free country for about 15 years (19). However, since the disease is active in the two neighboring countries Afghanistan and Pakistan (15), the risk of re-emergence of wild polio virus due to importation is high. Figure 1 shows Iran's geographical location.



Figure 1. Iran's Geographical Location

Current immunization coverage with three doses of oral polio vaccine in children under one year is more than 95% (19). Another study also estimated that the coverage of polio vaccination with six doses of oral polio vaccine (OPV) is also more than 94% in Iran (22).

3.7. AFP and VAPP Reports in Iran

Acute flaccid paralysis (AFP) is a clinical manifestation characterized by reduced muscle tone (weakness) or paralysis. The causes of AFP are as follows:

Guillain-Barre syndrome, acute axonal neuropathy, neuropathies of infectious diseases such as diphtheria and Lyme disease, acute toxic neuropathies by heavy metals, arthropod bites, focal mono neuropathy, dermatomyositis, periodic paralyzes, corticosteroids and blocking agents, Post viral myositis, myasthenia gravis, botulism, poisoning by organophosphoric insecticides, tick bite

paralysis, snake bites, acute porphyrias, critical illness neuropathy, acute myopathy in patients attended to the intensive care unit (ICU), cord compression, multiple sclerosis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), ischemic cord damage and vaccine-associated paralytic poliomyelitis (23).

Vaccine-associated paralytic poliomyelitis (VAPP) is an uncommon side effect of oral polio vaccine. Moussavi et al., in their report entitled "polio eradication in Iran" stated the main causes of AFP as follows:

Guillain-Barre syndrome (the most common cause), cerebral nervous infarctions, transverse myelitis, myelopathy, cerebral palsy, peripheral neuropathy, ADEM, metabolic disorders, synovitis, ischemic encephalopathy, acute lymphocytic leukemia (ALL), myositis, hereditary neuropathy and mediastinal teratoma (5).

There is an appropriate surveillance system in Iran's health network. In this system, all the target diseases, including AFP are monitored (5).

According to Moussavi et al., the lowest rate of non-polio AFP was observed in Semnan province, Iran, with 1.4% and the highest one in Mazandaran province with 6.3%. The total reported cases in Iran were 622 with a total rate of 3.3% in 2010.

The following table shows flaccid paralysis cases caused by wild polio virus and oral polio vaccine in Iran and the three mentioned countries compared to Iran in 2014 and 2015 (9-15).

The total number of reported cases of non-polio was 708 in 2013 (4 per 100000, among under 15 years population) (19).

Soltani et al. conducted an observational study on 139 children aged < 15 years with AFP from January 2000 to December 2010 in Kurdistan, Iran. In this study, in 138 (99%) stool samples no poliovirus was isolated and none of them were diagnosed with polio. They concluded that to monitor AFP, the key requirement is an appropriate surveillance system (24).

Naeini et al. in a cross-sectional survey, reviewed the records of youth under 15-year-old with AFP in Isfahan province, Iran, from 2007 to 2013. All the cases were visited and three stool samples were collected from each of them and sent to the national polio laboratory for poliovirus isolation. In this study, 85 cases were analyzed, 54 males (63.5%) and 31 females (36.5%). The mean age of the patients was 5.7 ± 3.9 years. The most common cause (83.5%) of paralysis among these patients was Guillain-Barre syndrome. No poliomyelitis was found in this study except one case of vaccine associated poliomyelitis (VAPV) (22). Guillain-Barré syndrome was also the most frequent final diagnosis in the report by Soltani et al. (24). Poorolajal et al. in an eight-year surveillance of 88 children with non-

polio AFP, aged < 15 in Hamadan, Iran, reported 74 patients (84.0%) with complete paralysis. Guillain-Barré syndrome was the major leading cause of AFP in these children and in none of them wild polioviruses were detected (25). Salehiomran et al. showed high incidence of Guillain-Barré syndrome among AFP cases (26).

Shahmahmoodi et al., isolated type 3 immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) in a 15-month-old Iranian boy with AFP in 2008. All of the seven contacts, who had been tested, were negative for polio and no secondary AFP cases were found (27).

Dehghani et al. reported that 80% of the liver transplant recipients had protective antibody titers for poliomyelitis (28).

Li et al. investigated the polio virus excretion in a total of 562 PID cases from 2008 to 2013. In this study, 17 patients (3%) shed poliovirus from the stool, but none of them were developed paralysis during the study period. They concluded that, surveillance for polioviruses among the patients with immune disorders should be established (16).

Rahimi et al. reported three AFP cases with paralysis in which Sabin-like type 1 polioviruses (neurovirulent) were isolated in Iran in 2001 (29).

Parvaneh et al. in a case report described a fatal case of VAPP in an eight-month-old infant with major histocompatibility (MHC) class II deficiency (30).

Shahmahmoodi et al. in a study conducted on infants with immunodeficiency, determined the prevalence of VAPP from 1995 to 2008 in Iran. They suggested that, screening the neonates for immunodeficiency could reduce the risk for VAPP; thus, infants should be screened for immune disorders and inactivated polio vaccine should be used for them (31).

4. Discussion

To eradicate poliomyelitis from an area, using the vaccine alone is not enough. The other factors that coincide with the vaccination should be considered. Some of these factors include: geographical location (32, 33), water and food contaminated by human feces, non-healthy sewages, abundance of the insects in the environment (1, 34), low literacy, poor personal hygiene, being afraid of vaccine complications (35, 36), attitudinal factors, religion (32), political and security problems, lack of an appropriate and comprehensive health system, population immunity level, low rate of vaccination coverage, Inappropriate management of holding national immunization days (NIDs), economic poverty (37) including absence of an appropriate budget-

Table 1. Poliomyelitis and AFP Cases in Iran and Non-Eradicated Polio Countries in 2014 and 2015^a

| Country | AFP surveillance, 2015 AFP Cases Reported | Poliomyelitis Cases | | | |
|---------------------|--|---------------------|-----------|-----------|----------|
| | | 2014 | | 2015 | |
| | | WPV1 | cVDPV2* | WPV1 | cVDPV1 |
| Iran | 324 | 0 | 0 | 0 | 0 |
| Afghanistan | 1242 | 28 | 0 | 3 | 0 |
| Pakistan | 1964 | 306 | 22 | 25 | 0 |
| Nigeria | 5341 | 6 | 30 | 0 | 0 |
| Global total | 37258 | 359 | 55 | 28 | 0 |

^a AFP, acute flaccid paralysis; WPV1, wild poliovirus type 1; cVDPV1&2, circulatory-associated vaccine derived polio virus type 1 and 2.

ing system and low per capita for health, genetic factors (33), malnutrition, etc.

Hereunder, the status of each effective factor in non-eradicated polio countries is compared with that of Iran.

4.1. Geographical Location

Traditionally, it is known that the response of children in the tropical and developing countries to the oral polio vaccine is low. Iran is not located in a tropical zone (24, 32, 33); in the other words, it is known that children in the tropical and developing countries respond poorly to OPV (33). None of the two countries that are still contaminated by wild poliovirus, and also Iran, is classified among the tropical regions (38).

4.2. Contamination of Water by Human Feces and Non-Healthy Sewages

Poliomyelitis is a highly contagious disease mainly transmitted via the fecal-oral route. Studies show that drinking water in Pakistan and Nigeria is not safe (1, 35). Total population access to improved drinking water sources in 2015 is reported 22%, 47%, 90% and 94% in Afghanistan, Nigeria, Pakistan and Islamic Republic of Iran, respectively (39). Iran's health officials should continuously monitor the health of the Helmand River water flowing from Afghanistan to Iran (40).

4.3. Economic Poverty

Economic poverty (absence of an appropriate budgeting system and low per capita for health) is an important factor.

4.4. Low Literacy

In a study in 2014, female literacy rate in the world was 79.7%, in Afghanistan 12.6%, in Nigeria 50.4%, in Pakistan is 42% and in Iran 82.5% (41). Therefore, the literacy rate of the mothers in the addressed countries is lower than that of Iran.

4.5. Fear of Mothers from Vaccine Complications

The attenuated virus in OPV reverts into a form that can paralyze (36). Thus, the fear of vaccination is not a non-reasonable reaction.

4.6. Religious Factors

Religious extremists with wrong impressions from the religious orders are an important factor against using polio vaccine and they are a major factor in the failure of immunization programs against polio in Nigeria (41), Pakistan (42) and Afghanistan (43). In these countries, focusing on the communication strategies including dialogues with religious leaders, holding some individual meetings, seminars, workshops, campaigns and media programs is believed to be necessary to eliminate such misconceptions, which can in turn contribute to raising public awareness about the urgency of the need for polio vaccination. In Iran, more than 20 years ago when the national vaccination days were held, religious (Shia or Sunni) leaders encouraged people to participate in the vaccination programs.

4.7. Political and Security Issues

The world news repeatedly expresses the military attacks on Afghanistan and Pakistan. These attacks may lead to regional instability and migration of the people into Iran.

Based on the latest statistics, about 2.5 million Afghan refugees live in Iran (44). Therefore, it is very important to control and vaccinate the immigrants.

4.8. Lack of an Appropriate and Comprehensive Health System

Holding the national polio days requires a coordinated and powerful health care delivery system, and it seems that, in the countries where wild virus is still reported, this

system is not powerful. Appropriate management of holding national immunization days (NIDs) is directly associated with health delivery system in the countries. Some factors in this domain are weaknesses of policy making, planning, preparation and provision of a safe and effective vaccine, correct cold chain monitoring, organizing, mobilizing of manpower and implementing the mass vaccination on NIDs and continuing the vaccination monitoring. Iran's primary health care system is approved by the worldwide health authorities (45).

4.9. The Rate of Vaccination Coverage

Once the polio vaccine coverage is low, polioviruses vaccines may circulate among insufficiently immunized people and become pathogenic [46].

Estimated coverage of polio vaccination among infants aged < 1 year with three doses of OPV3, in 2013 was 90% in Afghanistan, 67% in Nigeria, and 66% in Pakistan (37). Current immunization coverage with three doses of OPV in Iran is more than 95% percent (19), and this coverage rate is sufficient to eradicate polio.

4.10. Genetic Factors

The role of genetics in polio is known (33), but, information is not available about the role of genetics in Iran, Afghanistan and Pakistan.

4.11. Recommended Vaccine for Iran

Despite using IPV in most of the developed countries, in Iran, OPV is still used.

As already mentioned, Iran is considered as a polio-free country since 2001; however its two neighboring countries, Afghanistan and Pakistan are still as two endemic countries for the wild virus. Therefore, especially in the areas around the geographical borders, using the OPV vaccine is preferred. In addition, using IPV or combined schedules (OPV + IPV) is not cost-effective (19).

4.12. Conclusions

Trivalent oral polio vaccine (tOPV) is a live and attenuated vaccine, consisting types 1, 2 and 3 of the polio viruses. The most important disadvantage of OPV is genetic instability, resulting in vaccine-associated paralytic poliomyelitis. The immune response against polio virus type 3 (PV3) was lower than those of other serotypes. Therefore, improving the population immunity against this serotype is an urgent priority. The wild polio virus is disrupted in most countries, except Afghanistan and Pakistan. The majority of VDPPs are associated with type 2 circulating VDPVs (cVDPV2). Therefore, it is suggested to remove type 2 virus from trivalent vaccines (tOPV) and change this vaccine to

bivalent vaccines (bOPV), consisting only types 1 and 3 polioviruses.

From 2014 to 2015, 324 non-polio paralyses were reported in Iran. Iran's health managers should continuously monitor the vaccination coverage with three doses of OPV in the level over 95%, monitor the health of the Helmand River water which flows from Afghanistan to Iran and vaccinate the immigrants.

Footnotes

Authors' Contribution: Study concept and design: Seyed Mansour Razavi and Masoud Mardani; acquisition of data: not applicable; analysis and interpretation of data: not applicable; drafting of the manuscript: Seyed Mansour Razavi, Masoud Mardani and Payman Salamati; critical revision of the manuscript for important intellectual content: Seyed Mansour Razavi, Masoud Mardani and Payman Salamati; statistical analysis: not applicable; administrative, technical, and material support: not applicable; study supervision: Seyed Mansour Razavi, Masoud Mardani and Payman Salamati.

Conflict of Interests: The authors declare no conflict of interests.

References

1. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-Derived Polioviruses And The Endgame Strategy For Global Polio Eradication. *Annu. Rev. Microbiol.* 2005;**59**:587-635.
2. Sutter WR, Stephen L. Cochi Poliomyelitis. In: Wallac BR, editor. *Maxy Rosenau Last Public Health and Preventive Medicine.* 15 ed. USA: McGraw-Hill; 2008. .
3. Emad MR, Pakmanesh K, Sedaghat P. Evaluation of sympathetic skin response in old-polio patients. *Iran Red Crescent Med J.* 2011;**13**(11):829-31. [PubMed: 22737423].
4. Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM, Centers for Disease C, et al. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015. *MMWR Morb Mortal Wkly Rep.* 2015;**64**(23):640-6. [PubMed: 26086635].
5. Moussavi T, Sadrizadeh B, Zahraei M, Nategh R, Nadim A. Polio eradication in Iran. *Arch Iran Med.* 2012;**15**(2):107-9. [PubMed: 22292583].
6. Ministry of Health and Medical Education DOH. Children immunization program in the Islamic Republic of Iran 2014. Available from: http://behdasht.gov.ir/uploads/1_96_1416123916612_1.pdf.
7. Oral polio vaccine (OPV). . Global Polio eradication initiative Geneva, Switzerland: Oral polio vaccine (OPV); 2010. Available from: [www.polioeradication.org/Polioandprevention/Thevaccines/Oralpoliovaccine\(OPV\).aspx](http://www.polioeradication.org/Polioandprevention/Thevaccines/Oralpoliovaccine(OPV).aspx).
8. Immunization Systems Management Group of the Global Polio Eradication I. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016. *MMWR Morb Mortal Wkly Rep.* 2015;**64**(25):699-702. [PubMed: 26135591].
9. World Health Organization (WHO). . Weekly epidemiological record. 90. ; 2015. pp. 337-48.

10. Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. *J Infect Dis.* 2014;**210** Suppl 1:283-93. doi: [10.1093/infdis/jiu295](https://doi.org/10.1093/infdis/jiu295). [PubMed: [25316847](https://pubmed.ncbi.nlm.nih.gov/25316847/)].
11. Mir F, Quadri F, Mach O, Ahmed I, Bhatti Z, Khan A, et al. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial. *Lancet Infect Dis.* 2015;**15**(8):889-97. doi: [10.1016/S1473-3099\(15\)00093-6](https://doi.org/10.1016/S1473-3099(15)00093-6). [PubMed: [26093979](https://pubmed.ncbi.nlm.nih.gov/26093979/)].
12. Izadi S, Shahmahmoodi S, Zahraei SM, Dorostkar F, Majdzadeh R. Risk of polio reintroduction to border regions of Islamic Republic of Iran: seroprevalence study of children with at least 5 doses of oral polio vaccine. *East Mediterr Health J.* 2014;**20**(5):287-94. [PubMed: [24952285](https://pubmed.ncbi.nlm.nih.gov/24952285/)].
13. Moriniere BJ, van Loon FP, Rhodes PH, Klein-Zabban ML, Frank-Senat B, Herrington JE, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. *Lancet.* 1993;**341**(8860):545-50. [PubMed: [8099637](https://pubmed.ncbi.nlm.nih.gov/8099637/)].
14. Habib MA, Soofi S, Sheraz A, Bhatti ZS, Okayasu H, Zaidi SZ, et al. Zinc supplementation fails to increase the immunogenicity of oral poliovirus vaccine: a randomized controlled trial. *Vaccine.* 2015;**33**(6):819-25. doi: [10.1016/j.vaccine.2014.12.001](https://doi.org/10.1016/j.vaccine.2014.12.001). [PubMed: [25500307](https://pubmed.ncbi.nlm.nih.gov/25500307/)].
15. World Health Organization. . WHO vaccine-preventable diseases: monitoring system 2014 global summary. Geneva, Switzerland: World Health Organization; 2015.
16. Li L, Ivanova O, Driss N, Tiongo-Recto M, da Silva R, Shahmahmoodi S, et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. *J Infect Dis.* 2014;**210** Suppl 1:368-72. doi: [10.1093/infdis/jiu065](https://doi.org/10.1093/infdis/jiu065). [PubMed: [25316857](https://pubmed.ncbi.nlm.nih.gov/25316857/)].
17. Shaghghi M, Parvaneh N, Ostad-Rahimi P, Fathi SM, Shahmahmoodi S, Abolhassani H, et al. Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. *Immunol Invest.* 2014;**43**(3):292-8. doi: [10.3109/08820139.2013.859156](https://doi.org/10.3109/08820139.2013.859156). [PubMed: [24294834](https://pubmed.ncbi.nlm.nih.gov/24294834/)].
18. Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M. Polio endgame: the global introduction of inactivated polio vaccine. *Expert Rev Vaccines.* 2015;**14**(5):749-62. doi: [10.1586/14760584.2015.1001750](https://doi.org/10.1586/14760584.2015.1001750). [PubMed: [25597843](https://pubmed.ncbi.nlm.nih.gov/25597843/)].
19. Moradi-Lakeh M, Esteghamati A. National Immunization Program in Iran: whys and why not. *Hum Vaccin Immunother.* 2013;**9**(1):112-4. doi: [10.4161/hv.22521](https://doi.org/10.4161/hv.22521). [PubMed: [23442584](https://pubmed.ncbi.nlm.nih.gov/23442584/)].
20. World Health Organization. Global Polio eradication initiative. Nigeria: World Health Organization, Global Polio Eradication Initiative; 2011.
21. Zahraei SM, Marandi A, Sadrizadeh B, Gouya MM, Rezaei P, Vazirian P, et al. Role of National Immunization Technical Advisory Group on improvement of immunization programmes in the Islamic Republic of Iran. *Vaccine.* 2010;**28** Suppl 1:35-8. doi: [10.1016/j.vaccine.2010.02.030](https://doi.org/10.1016/j.vaccine.2010.02.030). [PubMed: [20412994](https://pubmed.ncbi.nlm.nih.gov/20412994/)].
22. Naeini AE, Ghazavi M, Moghim S, Sabaghi A, Fadaei R. Acute flaccid paralysis surveillance: A 6 years study, Isfahan, Iran. *Adv Biomed Res.* 2015;**4**:99. doi: [10.4103/2277-9175.156670](https://doi.org/10.4103/2277-9175.156670). [PubMed: [26015925](https://pubmed.ncbi.nlm.nih.gov/26015925/)].
23. World Health Organization. . Causes of Acute Flaccid Paralysis (AFP) Worldwide. france: World Health Organization; 2013.
24. Soltani J, Esmailnasab N, Roshani D, Karimi M, Amjadi M. Acute flaccid paralysis and its differential diagnosis in in kurdistan province, Western iran; an 11-year surveillance. *Iran J Pediatr.* 2014;**24**(2):131-9. [PubMed: [25535530](https://pubmed.ncbi.nlm.nih.gov/25535530/)].
25. Poorolajal J, Ghasemi S, Farahani LN, Hosseini AS, Bathaei SJ, Zahiri A. Evaluation of acute flaccid paralysis in hamadan, iran from 2002 to 2009. *Epidemiol Health.* 2011;**33**:2011011. doi: [10.4178/epih/e2011011](https://doi.org/10.4178/epih/e2011011). [PubMed: [2211031](https://pubmed.ncbi.nlm.nih.gov/2211031/)].
26. Salehiomran MR, Naserkhaki S, Hajiahmadi M. Acute generalized weakness in patients referred to Amirkola Children's Hospital from 2005 to 2010. *Caspian J Intern Med.* 2012;**3**(2):425-7. [PubMed: [24358438](https://pubmed.ncbi.nlm.nih.gov/24358438/)].
27. Shahmahmoodi S, Parvaneh N, Burns C, Asghar H, Mamishi S, Tabatabaie H, et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. *Virus Res.* 2008;**137**(1):168-72. doi: [10.1016/j.virusres.2008.07.006](https://doi.org/10.1016/j.virusres.2008.07.006). [PubMed: [18674576](https://pubmed.ncbi.nlm.nih.gov/18674576/)].
28. Dehghani SM, Shakiba MA, Ziaeyan M, Imanieh MH, Haghghat M, Sedaghat M, et al. Evaluation of immunity status to routine vaccination in pediatric liver transplant candidates. *Turk J Gastroenterol.* 2014;**25** Suppl 1:26-31. doi: [10.5152/tjg.2014.5139](https://doi.org/10.5152/tjg.2014.5139). [PubMed: [25910330](https://pubmed.ncbi.nlm.nih.gov/25910330/)].
29. Rahimi P, Tabatabaie H, Gouya MM, Zahraei M, Mahmudi M, Ziaie A, et al. Characterization of mutations in the VP(1) region of Sabin strain type 1 polioviruses isolated from vaccine-associated paralytic poliomyelitis cases in Iran. *J Clin Virol.* 2007;**39**(4):304-7. doi: [10.1016/j.jcv.2007.04.017](https://doi.org/10.1016/j.jcv.2007.04.017). [PubMed: [17590391](https://pubmed.ncbi.nlm.nih.gov/17590391/)].
30. Parvaneh N, Shahmahmoudi S, Tabatabai H, Zahraei M, Mousavi T, Esteghamati AR, et al. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. *J Clin Virol.* 2007;**39**(2):145-8. doi: [10.1016/j.jcv.2007.04.002](https://doi.org/10.1016/j.jcv.2007.04.002). [PubMed: [17509935](https://pubmed.ncbi.nlm.nih.gov/17509935/)].
31. Shahmahmoodi S, Mamishi S, Aghamohammadi A, Aghazadeh N, Tabatabaie H, Gouya MM, et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995-2008. *Emerg Infect Dis.* 2010;**16**(7):1133-6. doi: [10.3201/eid1607.091606](https://doi.org/10.3201/eid1607.091606). [PubMed: [20587188](https://pubmed.ncbi.nlm.nih.gov/20587188/)].
32. Hatami H, Razavi SM, Eftekhari Ardabili H, Majlesi F. In: Public health comprehensive book. 3, editor. 2. Los Angeles: Arjomand publication; 2013. p. 1091.
33. Paul Y. Role of genetic factors in polio eradication: new challenge for policy makers. *Vaccine.* 2007;**25**(50):8365-71. doi: [10.1016/j.vaccine.2007.09.068](https://doi.org/10.1016/j.vaccine.2007.09.068). [PubMed: [17996995](https://pubmed.ncbi.nlm.nih.gov/17996995/)].
34. Christenson E, Bain R, Wright J, Aondoakaa S, Hossain R, Bartram J. Examining the influence of urban definition when assessing relative safety of drinking-water in Nigeria. *Sci Total Environ.* 2014;**490**:301-12. doi: [10.1016/j.scitotenv.2014.05.010](https://doi.org/10.1016/j.scitotenv.2014.05.010). [PubMed: [24858228](https://pubmed.ncbi.nlm.nih.gov/24858228/)].
35. List of countries by literacy rate Available from: http://en.wikipedia.org/wiki/List_of_countries_by_literacy_rate.
36. Shimizu H, Thorley B, Paladin FJ, Brussen KA, Stambos V, Yuen L, et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. *J Virol.* 2004;**78**(24):13512-21. doi: [10.1128/JVI.78.24.13512-13521.2004](https://doi.org/10.1128/JVI.78.24.13512-13521.2004). [PubMed: [15564462](https://pubmed.ncbi.nlm.nih.gov/15564462/)].
37. Delpeyroux F, Colbere-Garapin F, Razafindratsimandresy R, Sadeuh-Mba S, Joffret ML, Rousset D, et al. [Eradication of poliomyelitis and emergence of pathogenic vaccine-derived polioviruses: from Madagascar to Cameroon]. *Med Sci (Paris).* 2013;**29**(11):1034-41. doi: [10.1051/medsci/20132911021](https://doi.org/10.1051/medsci/20132911021). [PubMed: [24280508](https://pubmed.ncbi.nlm.nih.gov/24280508/)].
38. Gadget A. List of Tropical Countries Available from: <http://www.hobotraveler.com/tropical/list-of-tropical-countries.php41>.
39. The Guardian. . Access to clean water. The Guardian Available from: <http://www.theguardian.com/news/datablog/2009/mar/03/access-water>.
40. Helmand River i Geography. . Encyclopedia Iranica Available from: www.iranicaonline.org/articles/helmand-river-i.
41. Kapp C. Surge in polio spreads alarm in northern Nigeria. Rumours about vaccine safety in Muslim-run states threaten WHO's eradication programme. *Lancet.* 2003;**362**(9396):1631-2. [PubMed: [14631961](https://pubmed.ncbi.nlm.nih.gov/14631961/)].
42. Ahmad K. Pakistan struggles to eradicate polio. *Lancet Infect Dis.* 2007;**7**(4):247. [PubMed: [17419137](https://pubmed.ncbi.nlm.nih.gov/17419137/)].
43. Centers for Disease Control Prevention . Resurgence of wild poliovirus type 1 transmission and consequences of importation-21 countries, 2002-2005. *MMWR Morb Mortal Wkly Rep.* 2006;**55**(6):145-50. [PubMed: [16484977](https://pubmed.ncbi.nlm.nih.gov/16484977/)].
44. Jahan News. The latest statistics of the number of Afghan refugees in Iran 2015. Available from: <http://jahannews.com/vdcb95basrhhb55p.uur.html>.
45. Asaei SE. Iran's Excellent Primary Health Care System Available from: www.unicef.org/iran/media_4427.html.